Ever since Xconomy added New York to its stable of cities on April 1, we have found plenty of companies to write about that are making waves in tech, biotech, and cleantech. We’ve met tech entrepreneurs who’ve caught the fancy of New York’s thriving venture capital scene, and scientists in the bowels of Big Pharma laboring to invent the next blockbuster drugs. We’ve visited with CEOs in the rapidly growing biotech sector in and around NYC, and profiled so many new startup incubators we’ve lost count of them all.
To wrap up our first (partial) year in the Big Apple, we’re counting down the top 10 Xconomy topics, as measured by traffic. Why topics as opposed to stories? You’ll have to read all the way to the end to find out.
Our most popular topics of the year were….
10. Arno Therapeutics
Arno (OTCBB: ARNI), based in Parsippany, NJ, is what’s known as a “virtual biotech,” because it’s developing three drugs with just a handful of full-time employees who outsource almost every step of the research and development process. But it’s a mighty qualified handful—Arno is staffed by veterans of Johnson & Johnson, Pfizer, and Medimmune.
When New York’s leaders put out a request for proposals for a tech incubator in Harlem, entrepreneurs Marcus Mayo and Brian Shields responded with IncubateNYC, a multifaceted plan to bring technology startups to an area of the city that could use an economic revival.
The pharmaceutical industry is desperate for new technology to improve drug discovery. Pennington, NJ-based BioLeap believes it has a solution in a tech platform designed to predict how tightly experimental drugs will bind to their disease targets.
What do you get when you combine social media with financial services? Lenddo believes you get a great way to market small loans to the developing world’s emerging middle class.
NYC-based medical device maker Delcath Systems (NASDAQ: DCTH) has endured endless hassles from the FDA over its drug-device combo to treat liver cancer, and investors have been bailing out … Next Page »
By posting a comment, you agree to our terms and conditions.